Veracyte, Inc. VCYT
25.11 USD 0.00 (+0.00%)
Nov 12, 2026, 11:22 AM EST
24.07 Day range 25.21
21.91 52-week range 60.91
- YTD
- -40.36%
- 1 year
- -40.64%
News
benzinga.com Stephens & Co. Maintains Overweight on Veracyte, Lowers Price Target to $40 Stephens & Co. analyst Mason Carrico maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $55 to $40.
seekingalpha.com Veracyte, Inc. (VCYT) Presents at 2026 UBS Global Healthcare Conference Transcript Veracyte, Inc. ( VCYT ) 2026 UBS Global Healthcare Conference November 10, 2026 4:15 PM EST Company Participants Marc Stapley - CEO & Director Rebecca Chambers - Executive VP & CFO Conference Call…
globenewswire.com Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Veracyte (VCYT) Veracyte's third-quarter report said Decipher Prostate volume came in below the Company's expectations, and full-year 2026 revenue guidance was narrowed as Decipher's annual volume projections were…
benzinga.com Piper Sandler Maintains Overweight on Veracyte, Lowers Price Target to $30 Piper Sandler analyst David Westenberg maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $54 to $30.
benzinga.com Freedom Capital Markets Maintains Buy on Veracyte, Lowers Price Target to $40 Freedom Capital Markets analyst Keith Hinton maintains Veracyte (NASDAQ:VCYT) with a Buy and lowers the price target from $66 to $40.
businesswire.com VCYT Investors Have Opportunity to Join Veracyte, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $VCYT--VCYT Investors Have Opportunity to Join Veracyte, Inc. Fraud Investigation with SBS Law.
benzinga.com UBS Maintains Buy on Veracyte, Lowers Price Target to $35 UBS analyst Doug Schenkel maintains Veracyte (NASDAQ:VCYT) with a Buy and lowers the price target from $65 to $35.
defenseworld.net Veracyte (NASDAQ:VCYT) Sees Unusually-High Trading Volume – Still a Buy? Shares of Veracyte, Inc. (NASDAQ: VCYT - Get Free Report) saw unusually-high trading volume on Friday. 1,904,920 shares traded hands during trading, an increase of 57% from the average daily volume…
zacks.com Veracyte Q3 Earnings Call Highlights Slower Growth and Added Investment VCYT beats Q3 earnings estimates but trims its 2026 revenue outlook as Decipher growth slows and investments in breast and bladder cancer testing rise.
prnewswire.com VCYT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Veracyte /PRNewswire/ -- A $100 million buyback authorization and $151.8 million in third-quarter revenue did not hold up Veracyte, Inc. (NASDAQ: VCYT) shares, which
seekingalpha.com Veracyte, Inc. (VCYT) Q3 2026 Earnings Call Transcript Veracyte, Inc. ( VCYT ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Kelly Gura - Director of Investor Relations Marc Stapley - CEO & Director Rebecca Chambers - Executive…
prnewswire.com Veracyte Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Veracyte (VCYT) Veracyte stock fell more than 50% after the Company reported on November 4, 2026 that Decipher Prostate volume fell short of its expectations. Levi and Korsinsky investigates into potential…
globenewswire.com VCYT Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud Against Veracyte, Inc. VCYT's stock is down more than 50%; Ademi LLP is investigating Veracyte for potential securities fraud. CLICK HERE TO JOIN MILWAUKEE, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Lakewood-Amedex (NASDAQ:LABT) shares moved upwards by 237.6% to $0.65 during Thursday's regular session. ADMA Biologics (NASDAQ:ADMA) stock increased by 25.62% to $13.16. The market value of…
benzinga.com Nasdaq Tumbles 4.5%; Cardinal Health Shares Gain After Upbeat Q1 Earnings U.S. stocks tumbled: Nasdaq -4.5%, S&P 500 -3.3%, Dow -2.5%. Cardinal Health rose on strong results; AppLovin surged 32%, while Veracyte fell 55%.
benzinga.com Why Is Veracyte Stock Sinking Thursday? Veracyte (VCYT) stock tumbled 54% to a new 52-week low as weaker-than-expected Decipher Prostate test volumes overshadowed Q3 earnings beat.
benzinga.com Dow Surges 250 Points; US Weekly Jobless Claims Fall U.S. stocks mixed: Dow +0.47%, Nasdaq -1.35%, S&P 500 -0.55%. Jobless claims fell to 189,000; oil and gold rose.
benzinga.com Zillow Posts Downbeat Q3 Results, Joins HubSpot, Snap And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures were mixed as Zillow and several companies fell sharply premarket after weak results and lowered sales guidance.
benzinga.com Leerink Partners Downgrades Veracyte to Market Perform, Lowers Price Target to $35 Leerink Partners analyst Puneet Souda downgrades Veracyte (NASDAQ:VCYT) from Outperform to Market Perform and lowers the price target from $55 to $35.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers ADMA Biologics (NASDAQ:ADMA) shares rose 19.6% to $12.53 during Thursday's pre-market session. The market value of their outstanding shares is at $2.3 billion. As per the news, the Q3…
benzinga.com Needham Maintains Buy on Veracyte, Lowers Price Target to $46 Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and lowers the price target from $69 to $46.
benzinga.com Why AppLovin Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket AppLovin surged 16.5% premarket after Q3 revenue and EPS beat estimates and Q4 guidance topped forecasts; MNTN plunged 42.3% on weak results.
marketbeat.com What Veracyte (VCYT) Said on Its Q3 Earnings Call Veracyte NASDAQ: VCYT reported 15% revenue growth for the third quarter of 2026, but lowered its near-term expectations for its Decipher Prostate test after volume came in below management's…
benzinga.com Veracyte Q3 2026 Earnings Call Transcript Veracyte (NASDAQ:VCYT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…- benzinga.com Veracyte Narrows FY2026 Sales Guidance from $590.000M-$596.000M to $590.000M-$593.000M vs $593.894M Est Veracyte (NASDAQ:VCYT) narrows FY2026 sales outlook from $590.000 million-$596.000 million to $590.000 million-$593.000 million vs $593.894 million estimate.
- benzinga.com Veracyte Q3 Adj. EPS $0.51 Beats $0.41 Estimate, Sales $151.754M Beat $147.439M Estimate Veracyte (NASDAQ:VCYT) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.41 by 24.39 percent. This is unchanged from the same period last year. The…
- benzinga.com Veracyte Announces Receiving Of Coverage For Its Prosigna Breast Risk Of Recurrence Test For Its Technical Assessment Submission Through Palmetto GBA’s MolDX Program Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Prosigna® Breast Risk of Recurrence (ROR) test has received coverage for its Technical Assessment…
benzinga.com Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia, extending its CRISPR bet to 50 sessions.- benzinga.com Veracyte To Present New Findings From Retrospective Ancillary Analysis Of Randomized Phase III NRG/RTOG 0815 Trial At 2026 ASTRO Annual Meeting Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced that new findings from a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial will be…
benzinga.com Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.- benzinga.com Veracyte Acquires Convergent Genomics In $150M Deal, With Up To $30M Milestone Payments Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced its acquisition of Convergent Genomics. The acquisition adds Convergent Genomics’ UroAmp platform, including its…
benzinga.com UBS Maintains Buy on Veracyte, Raises Price Target to $65 UBS analyst Doug Schenkel maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $52 to $65.
benzinga.com Top 3 Health Care Stocks That Could Blast Off This Month The health care sector's oversold stocks present buying opportunities for undervalued companies. RSI compares stock strength on up and down days, with an RSI below 30 considered oversold.- benzinga.com Piper Sandler Maintains Overweight on Veracyte, Lowers Price Target to $54 Piper Sandler analyst David Westenberg maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $66 to $54.
- benzinga.com Stephens & Co. Maintains Overweight on Veracyte, Lowers Price Target to $55 Stephens & Co. analyst Mason Carrico maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $68 to $55.
benzinga.com Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $44 Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and lowers the price target from $47 to $44.- benzinga.com Canaccord Genuity Maintains Hold on Veracyte, Lowers Price Target to $50 Canaccord Genuity analyst Kyle Mikson maintains Veracyte (NASDAQ:VCYT) with a Hold and lowers the price target from $60 to $50.
benzinga.com Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures rise, Nasdaq 100 up 300 points. Apple Inc shares fall 7.4% despite beating analyst estimates for Q3. Other stocks also dip in pre-market.- benzinga.com Needham Maintains Buy on Veracyte, Raises Price Target to $69 Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $57 to $69.
- benzinga.com Veracyte Raises FY2026 Sales Guidance from $582.000M-$592.000M to $590.000M-$596.000M vs $586.445M Est Veracyte (NASDAQ:VCYT) raises FY2026 sales outlook from $582.000 million-$592.000 million to $590.000 million-$596.000 million vs $586.445 million estimate.
benzinga.com This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Wall Street analysts initiated coverage on various top stocks, including VCYT, UMAC, FISN, LTRX, and TNGX with positive ratings and price targets.- benzinga.com Piper Sandler Initiates Coverage On Veracyte with Overweight Rating, Announces Price Target of $66 Piper Sandler analyst David Westenberg initiates coverage on Veracyte (NASDAQ:VCYT) with a Overweight rating and announces Price Target of $66.
- benzinga.com Canaccord Genuity Maintains Hold on Veracyte, Raises Price Target to $60 Canaccord Genuity analyst Kyle Mikson maintains Veracyte (NASDAQ:VCYT) with a Hold and raises the price target from $42 to $60.
- benzinga.com Morgan Stanley Maintains Underweight on Veracyte, Raises Price Target to $47 Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and raises the price target from $37 to $47.
- benzinga.com Guggenheim Maintains Buy on Veracyte, Raises Price Target to $65 Guggenheim analyst Subbu Nambi maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $45 to $65.
benzinga.com Cathie Wood Sells Robinhood Stock, Doubles Down On This George Soros-Backed AI Stock On Wednesday, June 10, 2026, Ark Invest sold $7.8M in Robinhood shares Wednesday while adding 141,502 shares of Kodiak AI- benzinga.com Needham Maintains Buy on Veracyte, Raises Price Target to $57 Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $48 to $57.
benzinga.com Veracyte Commercially Rolls Out Prosigna Breast Risk Of Recurrence Test Across U.S. On the heels of the landmark OPTIMA trial readout presented at the ASCO Annual Meeting, Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced the U.S. commercial launch…- benzinga.com Veracyte To Present Results From Independent OPTIMA Trial, Led By University College London, At ASCO Annual Meeting Highest level of prospective evidence supports test-directed chemotherapy decisions in broadest high-risk population to-date, including premenopausal women and patients with extensive lymph node…
- benzinga.com Canaccord Genuity Maintains Hold on Veracyte, Raises Price Target to $42 Canaccord Genuity analyst Kyle Mikson maintains Veracyte (NASDAQ:VCYT) with a Hold and raises the price target from $40 to $42.